公开(公告)号：EP2087888A1

公开(公告)日：2009-08-12

申请号：EP09160652.5

申请日：2004-02-24

申请人： Novacardia, Inc.

发明人： Otsuki, Lauren ,  Dittrich, Howard ,  Widder, Kenneth, J. ,  Blantz, Roland ,  Thomson, Scott

IPC分类号： A61K31/138 ,  A61K31/522 ,  A61K31/135 ,  A61K31/40 ,  A61K31/47 ,  A61K31/403 ,  A61K31/55 ,  A61K31/675 ,  A61K31/472 ,  A61K31/4178 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/41 ,  A61P9/04 ,  A61P9/10 ,  A61P13/12

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/40 ,  A61K31/401 ,  A61K31/403 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4745 ,  A61K31/522 ,  A61K31/55 ,  A61K31/675 ,  A61K2300/00

摘要： The present invention relates to adenosine A 1 receptor antagonists (AA 1 RA), for use in treating alkalosis.

摘要翻译： 本发明涉及用于治疗碱中毒的腺苷A 1受体拮抗剂（AA 1 RA）。

公开(公告)号：EP1620107A1

公开(公告)日：2006-02-01

申请号：EP04760339.4

申请日：2004-04-23

申请人： Novacardia, Inc.

发明人： WIDDER, Kenneth J., ,  OTSUKI, Lauren ,  DITTRICH, Howard ,  THOMSON, Scott ,  BLANTZ, Roland

IPC分类号： A61K31/522 ,  A61K31/635 ,  A61K31/63 ,  A61P7/10

CPC分类号： A61K45/06 ,  A61K31/405 ,  A61K31/522 ,  A61K31/63 ,  A61K31/635 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

公开(公告)号：EP2035009A1

公开(公告)日：2009-03-18

申请号：EP07796202.5

申请日：2007-06-14

申请人： Novacardia, Inc.

发明人： DITTRICH, Howard ,  FARMER, Brian ,  WOODS, Randy

IPC分类号： A61K31/522 ,  A61P9/04 ,  A61P13/12

CPC分类号： A61K31/522

摘要： A method for treating a patient, comprising providing a therapeutically-effective amount of an AA1RA to the patient; and informing the patient or a medical care worker that administration of the AA1RA can provide an improvement in renal function that persists for a time period following administration of the AA1RA, and wherein the time period is at least 3 days.

公开(公告)号：EP1932529A1

公开(公告)日：2008-06-18

申请号：EP08102364.0

申请日：2004-04-23

申请人： Novacardia, Inc.

发明人： Widder, Kenneth ,  Otsuki, Lauren ,  Dittrich, Howard ,  Thomson, Scott ,  Blantz, Roland

IPC分类号： A61K31/522 ,  A61K31/635 ,  A61K31/63 ,  A61P7/10

CPC分类号： A61K31/405 ,  A61K31/522 ,  A61K31/63 ,  A61K31/635 ,  A61K45/06 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic ,Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount ofKW.3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect

摘要翻译： 公开了包含治疗有效量的KW-3902或其盐，酯，酰胺，代谢物或前药以及非腺苷改性利尿剂的药物组合物。还公开了在动物中诱导利尿作用的方法，包括 给予治疗有效量的KW.3902或其盐，酯，酰胺，代谢物或前药与能够诱导利尿作用的第二药物组合物组合的步骤

公开(公告)号：EP1928414A2

公开(公告)日：2008-06-11

申请号：EP06748976.5

申请日：2006-03-31

申请人： Novacardia, Inc.

发明人： MUGERDITCHIAN, Mark ,  FIGUEROA, Maria S. Bruno

IPC分类号： A61K9/107 ,  A61K31/522 ,  A61P7/10

CPC分类号： A61K31/522 ,  A61K9/0019 ,  A61K9/1075

摘要： Disclosed are methods of producing an emulsion comprising determining a desired final pH of the emulsion, mixing an oil, surfactant, stabilizer, and a water-insoluble pharmaceutical, adjusting the pH of the mixture, and homogenizing the mixture, such that the starting pH of the mixture, the rotation speed of the homogenizer, and the temperature at which the homogenization is carried out are adjusted to give the desired pH.

公开(公告)号：EP2035092A2

公开(公告)日：2009-03-18

申请号：EP07796072.2

申请日：2007-06-12

申请人： Novacardia, Inc.

发明人： DITTRICH, Howard ,  FARMER, Brian ,  WOODS, Randy

IPC分类号： A61P7/10 ,  A61K31/4985 ,  A61K31/635 ,  A61K45/06

CPC分类号： A61K45/06 ,  A61K31/4985 ,  A61K31/635

摘要： Methods of treating patients with acute fluid overload comprising administering diuretic therapy and an amount of KW-3902, a pharmaceutically acceptable salt, ester, amide, metabolite, or prodrug thereof, effective to accelerate removal of excess fluid from the patient in comparison to diuretic therapy alone. Methods of improving the treatment time to achieve adequate diuresis in an individual experiencing acute fluid overload comprising administering to said individual a diuretic and a therapeutically effective amount of KW-3902 or a pharmaceutically acceptable salt, ester, amide, metabolite, or prodrug thereof.

公开(公告)号：EP2034992A2

公开(公告)日：2009-03-18

申请号：EP07796074.8

申请日：2007-06-12

申请人： Novacardia, Inc.

发明人： DITTRICH, Howard ,  FARMER, Brian ,  WOODS, Randy

IPC分类号： A61K31/405 ,  A61K31/522 ,  A61K31/635 ,  A61K45/06 ,  A61P13/12

CPC分类号： A61K45/06 ,  A61K31/405 ,  A61K31/522 ,  A61K31/635 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

公开(公告)号：EP1603545A2

公开(公告)日：2005-12-14

申请号：EP04714224.5

申请日：2004-02-24

申请人： Novacardia, Inc.

发明人： OTSUKI, Lauren ,  DITTRICH, Howard, C. ,  WIDDER, Kenneth, J. ,  BLANTZ, Roland ,  THOMSON, Scott

IPC分类号： A61K31/138 ,  A61K31/522 ,  A61K31/135 ,  A61K31/40 ,  A61K31/47 ,  A61K31/403 ,  A61K31/55 ,  A61K31/675 ,  A61K31/472 ,  A61K31/4178 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/41 ,  A61P9/04 ,  A61P9/10

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/40 ,  A61K31/401 ,  A61K31/403 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4745 ,  A61K31/522 ,  A61K31/55 ,  A61K31/675 ,  A61K2300/00

摘要： Disclosed are pharmaceutical composition comprising a beta-blocker and an adenosine A1 receptor antagonist (AA1RA), an angiotensin converting enzyme (ACE) inhibitor and an adenosine A1 receptor antagonist (AA1RA), and an angiotensin II receptor blocker (ARB) and an adenosine A1 receptor antagonist (AA1RA). Also disclosed are methods of treating cardiovascular disease, renal disease, alkalosis, or diabetic nephropathy comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.

公开(公告)号：EP2061793A2

公开(公告)日：2009-05-27

申请号：EP07811385.9

申请日：2007-08-17

申请人： Novacardia, Inc.

发明人： MUGERDITICHIAN, Mark ,  DITTRICH, Howard ,  FARMER, Brian ,  MURRAY, Thomas ,  KEANA, John

IPC分类号： C07D473/04 ,  C07D473/06 ,  C07D473/08 ,  C07D473/10 ,  C07D473/12 ,  C07D473/14 ,  C07D473/20 ,  C07D473/22 ,  A61K31/522 ,  A61K31/52 ,  A61P11/08 ,  A61P7/10

CPC分类号： C07D473/04 ,  C07D473/06

摘要： The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing KW-3902 derivatives of Formula (I), (II), (HI), (IV), (V), and (VI).

公开(公告)号：EP2001479A2

公开(公告)日：2008-12-17

申请号：EP07754928.5

申请日：2007-04-04

申请人： Novacardia, Inc.

发明人： DITTRICH, Howard ,  WEBER, Eckard ,  FARMER, Brian

IPC分类号： A61K31/52 ,  A61K31/5513 ,  A61K31/635 ,  A61P13/02

CPC分类号： A61K31/5513 ,  A61K31/19 ,  A61K31/195 ,  A61K31/515 ,  A61K31/52 ,  A61K31/522 ,  A61K31/55 ,  A61K31/635 ,  A61K31/7008 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions that include an AA1RA, or a salt, ester, amide, metabolite, or prodrug thereof, and an anticonvulsant agent. Also disclosed are methods of treating patients suffering from congestive heart failure, methods of improving renal function, and methods of restoring renal function comprising the step of administering a therapeutically effective amount of an AA1RA or a salt, ester, amide, metabolite, or prodrug thereof, in combination with an anticonvulsant agent.